Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of 64
million people globally. Although the incidence of HF has stabilised worldwide and seems to …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Background Guidelines recommend early initiation of multiple guideline-directed medical
therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and …

Given the high risk of adverse outcomes in patients with heart failure and reduced ejection
fraction (HFrEF), there is an urgent need for the initiation and titration of guideline-directed …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Aims To assess the association between combination, dose and use of current guideline‐
recommended target doses (TD) of renin–angiotensin system inhibitors (RASi), angiotensin …

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked
increases in death and rehospitalization rates, which then decline exponentially though they …

Heart failure (HF) is a major cause of mortality, hospitalizations, and reduced quality of life
and a major burden for the healthcare system. The number of patients that progress to an …

The syndrome of heart failure (HF) has historically been dichotomized based on clinical trial
inclusion criteria into patients with a reduced or preserved left ventricular ejection fraction …

Heart failure (HF) is a clinical syndrome with symptoms and or signs caused by a structural
and/or functional cardiac abnormality and associated with elevated natriuretic peptide levels …